Home/Biosimilar Atlas/Companies/Cinfa Biotech

Cinfa Biotech

Biosimilar developer, Spain. 1 development product across 1 molecule: pegfilgrastim.

First approval in the Atlas: Nov 2018, Pelmeg, pegfilgrastim (EMA)
FDAproducts approved0
EMAproducts approved1
MHRAproducts approved1
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered0
Connections
1molecule1product2 of 7markets0candidates in trials6companies on the same molecules

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
PegfilgrastimPelmeg / Cegfila B12019·Nov 2018MHRA····2/7

Month shown is the first approval or registration of that product in that market.

In development

ClinicalTrials.gov lists two comparative trials sponsored by Cinfa Biotech for one molecule: pegfilgrastim. All of these candidates already have at least one approval in the seven markets.

MoleculeCandidateDeveloper or sponsorReference productPhaseDesignRegistry statusStartedPrimary completionIn the AtlasRegistry record
PegfilgrastimB12019Cinfa BiotechNeulastaPhase 1Comparative PKCompletedNov 2015Jul 2016Pelmeg / CegfilaNCT02629562
PegfilgrastimB12019Cinfa BiotechNeulastaPhase 1Comparative PKCompletedSep 2016May 2017Pelmeg / CegfilaNCT02912377

Registry data from ClinicalTrials.gov, entered by the sponsors and not verified by any regulator. Status and dates are as posted; sponsors often update them late. Trials registered only on other registries, such as India's CTRI or China's ChiCTR, are not included. Checked 12 Sep 2026.

Companies on the same molecules

Developers whose portfolios overlap most with Cinfa Biotech, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

Biocon BiologicsOne shared molecule: pegfilgrastim9 molecules in its portfolioCoherus BioSciencesOne shared molecule: pegfilgrastim2 molecules in its portfolioCuraTeQ BiologicsOne shared molecule: pegfilgrastim4 molecules in its portfolioDr. Reddy's LaboratoriesOne shared molecule: pegfilgrastim6 molecules in its portfolioFresenius KabiOne shared molecule: pegfilgrastim5 molecules in its portfolioGennova BiopharmaceuticalsOne shared molecule: pegfilgrastim2 molecules in its portfolio

Chronology

Compare Cinfa Biotech with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.